

Labor Dr. Brunner adopts QuantaMatrix dRAST solution in routine clinical use

- **QuantaMatrix's direct Rapid Antimicrobial Susceptibility Testing system (dRAST™) improves optimal prescription of antibiotics by two days compared to conventional methods - thanks to gram-negative and gram-positive sepsis-causing bacteria panels**
- **Follows successful adoption of dRAST solution in routine clinical use in clinical laboratories in Europe and Asia**

QuantaMatrix, an *in vitro* diagnostics company specializing in the discovery, development and commercialization of fully integrated solutions within the sepsis value chain, today announces that its dRAST™ solution has been adopted for routine clinical use in Labor Dr. Brunner, a German-based medical diagnostic laboratory. dRAST implementation continues to be supported thanks to a solid partnership between QuantaMatrix Europe, a fully owned affiliate of QuantaMatrix Inc., based in Paris (France) and Axonlab, one of the leading *in vitro* diagnostics solution providers in Europe.

Part of a constantly evolving rapid AST (Antimicrobial Susceptibility Testing) market, the dRAST solution confirms its presence in Europe and Asia with this additional clinical site - at Labor Dr. Brunner. This latest implementation joins a list of current users that includes Seoul National University Hospital, Chungnam National University Hospital, the Catholic University of Korea Seoul St. Mary's Hospital, Konkuk University Medical Center, Eunpyeong St Mary's Hospital, Ehwa Womans University Morkdong Hospital, the Limbach Group in Germany and admed laboratory in Switzerland.

Labor Dr. Brunner was founded by Dr. Brunner in Constance, Germany in 1977. It started as a straightforward sample analysis laboratory, based on the premises of a former general practice clinic. Now, over 45 years later, Labor Dr. Brunner is able to analyze several thousand samples daily. The progressive and innovative nature of the team at Labor Dr. Brunner strengthens its commitment to providing the best quality of care for every patient. It uses the most cutting-edge technologies, including dRAST, which is now a fully integrated solution in routine clinical use.

"We are sure that the introduction of the dRAST system, which accelerates the routine diagnostic process, will reduce mortality for patients with sepsis and lead to a reduction in consequential damages," said Prof. Johannes Zander, laboratory medicine specialist at Labor Dr. Brunner.

"We are happy to announce this new adoption of our dRAST solution by Labor Dr. Brunner, an innovative laboratory with values that align with our own," said Sunghoon Kwon, CEO of QuantaMatrix. "This latest implementation for QuantaMatrix proves the need for a faster and more

reliable diagnostic process for sepsis patients.”

QuantaMatrix’s dRAST aims to help clinicians by providing optimal antibiotic treatments for sepsis patients. Its gram-negative and gram-positive antibiotic panels deliver fast results for a large variety of sepsis-causing bacteria. Sepsis is the body’s extreme response to a bacterial infection in the blood stream. When this occurs, septic shock triggers a chain reaction through the body that leads to tissue damage, organ failure and, if left untreated, death. Globally, today, sepsis claims a life every 2.8 seconds. Statistically, sepsis is the number one cause of death in hospitals, with a 30-day mortality rate of 20 to 30 per cent. The treatment of sepsis is a fight against time. Any delay in treatment after the onset of hypotension during septic shock reduces the survival rate of a patient by 7-9% per hour. The dRAST solution contains various innovative patents and a collection of over 30 million data points on bacteria growth to cut down diagnostic time from several days to as little as four hours.

About QuantaMatrix

QuantaMatrix Inc. is an *in vitro* diagnostics company specializing in the discovery, development and commercialization of fully-integrated solutions within the sepsis value chain. It has successfully established a network of distribution all over Europe. As it continues to expand, QuantaMatrix is now addressing the Middle East and Africa. It specializes in *in vitro* diagnostics using microbial diagnostics technology.

QuantaMatrix’s flagship product is its dRAST™ solution, a direct Rapid Antimicrobial Susceptibility Testing system, which is capable of finding the optimal antibiotic in as little as four hours following a positive blood culture. The dRAST solution uses various patented technologies related to optics, microfluidic engineering and artificial intelligence. Compared to conventional methods, dRAST effectively shortens the time to results by two to three days.

The dRAST solution is available in Korea, Europe and the Middle East, where QuantaMatrix has a distribution network spanning 26 countries. www.quantamatrix.com